Trump’s April 5 directive signals an “opening move in a chess match designed to attain some negotiating leverage with China,” ITIF’s Stephen Ezell told Bloomberg BNA. “If we came to a point in three to six months where tariffs on those products were applied, that would potentially disrupt an innovation ecosystem and the life sciences on both sides of the Pacific. It could raise prices for patients, potentially.”
